PSA is often tracked in patients receiving T therapy given the historical belief that T promotes prostate cancer growth; however, recent evidence and meta-analyses suggest that T therapy does not appear to significantly increase PSA levels or cause prostate cancer progression [25,26]. Here, KLK3 is linked to prostate cancer.